Transdermal selegiline and intravenous cocaine: Safety and interactions

Elisabeth J. Houtsmuller, Lisa D. Notes, Thomas Newton, Nicolette Van Sluis, Nora Chiang, Ahmed Elkashef, George Bigelow

Research output: Contribution to journalArticle

Abstract

Rationale: Because the dopamine system appears to be involved in both acute and chronic effects of cocaine, medication development efforts for cocaine addiction have focused largely on agents that interact with the dopamine system. Selegiline, a selective monoamine oxidase B inhibitor, indirectly modulates dopamine levels, and research suggests selegiline may modify subjective effects of cocaine. Objectives: To evaluate further the safety and potential of transdermal selegiline as a treatment for cocaine dependence, interactions between transdermal selegiline and intravenous cocaine were studied in cocaine-dependent volunteers. Methods: Pharmacokinetics and subjective, physiological, and endocrinological effects of intravenous cocaine (0,20 and 40 mg) were evaluated both before and during transdermal selegiline treatment (20 mg/day, 10 days) in 12 cocaine-dependent subjects. A transdermal selegiline formulation was used to avoid the risks associated with oral administration of MAO inhibitors. Results: Selegiline attenuated some physiological (systolic blood pressure and heart rate) and subjective (good effects, liking, stimulated, high, desire for cocaine) effects of cocaine. Selegiline did not affect cocaine's pharmacokinetics or cocaine-induced prolactin decrease and growth hormone increase. Conclusions: The combined administration of the transdermal selegiline patch and up to 40 mg cocaine was well tolerated. Selegiline may reduce physiological and subjective effects of cocaine. A randomized trial is needed to evaluate the efficacy of selegiline for cocaine abuse.

Original languageEnglish (US)
Pages (from-to)31-40
Number of pages10
JournalPsychopharmacology
Volume172
Issue number1
DOIs
StatePublished - Feb 2004

Fingerprint

Selegiline
Cocaine
Safety
Cocaine-Related Disorders
Dopamine
Monoamine Oxidase Inhibitors
Pharmacokinetics
Transdermal Patch
Blood Pressure
Monoamine Oxidase
Prolactin
Growth Hormone
Oral Administration
Volunteers

Keywords

  • Cocaine
  • Eldepryl
  • Endocrine
  • Human
  • Laboratory
  • Selegiline
  • Subjective

ASJC Scopus subject areas

  • Pharmacology

Cite this

Houtsmuller, E. J., Notes, L. D., Newton, T., Van Sluis, N., Chiang, N., Elkashef, A., & Bigelow, G. (2004). Transdermal selegiline and intravenous cocaine: Safety and interactions. Psychopharmacology, 172(1), 31-40. https://doi.org/10.1007/s00213-003-1616-6

Transdermal selegiline and intravenous cocaine : Safety and interactions. / Houtsmuller, Elisabeth J.; Notes, Lisa D.; Newton, Thomas; Van Sluis, Nicolette; Chiang, Nora; Elkashef, Ahmed; Bigelow, George.

In: Psychopharmacology, Vol. 172, No. 1, 02.2004, p. 31-40.

Research output: Contribution to journalArticle

Houtsmuller, EJ, Notes, LD, Newton, T, Van Sluis, N, Chiang, N, Elkashef, A & Bigelow, G 2004, 'Transdermal selegiline and intravenous cocaine: Safety and interactions', Psychopharmacology, vol. 172, no. 1, pp. 31-40. https://doi.org/10.1007/s00213-003-1616-6
Houtsmuller EJ, Notes LD, Newton T, Van Sluis N, Chiang N, Elkashef A et al. Transdermal selegiline and intravenous cocaine: Safety and interactions. Psychopharmacology. 2004 Feb;172(1):31-40. https://doi.org/10.1007/s00213-003-1616-6
Houtsmuller, Elisabeth J. ; Notes, Lisa D. ; Newton, Thomas ; Van Sluis, Nicolette ; Chiang, Nora ; Elkashef, Ahmed ; Bigelow, George. / Transdermal selegiline and intravenous cocaine : Safety and interactions. In: Psychopharmacology. 2004 ; Vol. 172, No. 1. pp. 31-40.
@article{e66214c627f945d7a52fa41b4a7a7cec,
title = "Transdermal selegiline and intravenous cocaine: Safety and interactions",
abstract = "Rationale: Because the dopamine system appears to be involved in both acute and chronic effects of cocaine, medication development efforts for cocaine addiction have focused largely on agents that interact with the dopamine system. Selegiline, a selective monoamine oxidase B inhibitor, indirectly modulates dopamine levels, and research suggests selegiline may modify subjective effects of cocaine. Objectives: To evaluate further the safety and potential of transdermal selegiline as a treatment for cocaine dependence, interactions between transdermal selegiline and intravenous cocaine were studied in cocaine-dependent volunteers. Methods: Pharmacokinetics and subjective, physiological, and endocrinological effects of intravenous cocaine (0,20 and 40 mg) were evaluated both before and during transdermal selegiline treatment (20 mg/day, 10 days) in 12 cocaine-dependent subjects. A transdermal selegiline formulation was used to avoid the risks associated with oral administration of MAO inhibitors. Results: Selegiline attenuated some physiological (systolic blood pressure and heart rate) and subjective (good effects, liking, stimulated, high, desire for cocaine) effects of cocaine. Selegiline did not affect cocaine's pharmacokinetics or cocaine-induced prolactin decrease and growth hormone increase. Conclusions: The combined administration of the transdermal selegiline patch and up to 40 mg cocaine was well tolerated. Selegiline may reduce physiological and subjective effects of cocaine. A randomized trial is needed to evaluate the efficacy of selegiline for cocaine abuse.",
keywords = "Cocaine, Eldepryl, Endocrine, Human, Laboratory, Selegiline, Subjective",
author = "Houtsmuller, {Elisabeth J.} and Notes, {Lisa D.} and Thomas Newton and {Van Sluis}, Nicolette and Nora Chiang and Ahmed Elkashef and George Bigelow",
year = "2004",
month = "2",
doi = "10.1007/s00213-003-1616-6",
language = "English (US)",
volume = "172",
pages = "31--40",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Transdermal selegiline and intravenous cocaine

T2 - Safety and interactions

AU - Houtsmuller, Elisabeth J.

AU - Notes, Lisa D.

AU - Newton, Thomas

AU - Van Sluis, Nicolette

AU - Chiang, Nora

AU - Elkashef, Ahmed

AU - Bigelow, George

PY - 2004/2

Y1 - 2004/2

N2 - Rationale: Because the dopamine system appears to be involved in both acute and chronic effects of cocaine, medication development efforts for cocaine addiction have focused largely on agents that interact with the dopamine system. Selegiline, a selective monoamine oxidase B inhibitor, indirectly modulates dopamine levels, and research suggests selegiline may modify subjective effects of cocaine. Objectives: To evaluate further the safety and potential of transdermal selegiline as a treatment for cocaine dependence, interactions between transdermal selegiline and intravenous cocaine were studied in cocaine-dependent volunteers. Methods: Pharmacokinetics and subjective, physiological, and endocrinological effects of intravenous cocaine (0,20 and 40 mg) were evaluated both before and during transdermal selegiline treatment (20 mg/day, 10 days) in 12 cocaine-dependent subjects. A transdermal selegiline formulation was used to avoid the risks associated with oral administration of MAO inhibitors. Results: Selegiline attenuated some physiological (systolic blood pressure and heart rate) and subjective (good effects, liking, stimulated, high, desire for cocaine) effects of cocaine. Selegiline did not affect cocaine's pharmacokinetics or cocaine-induced prolactin decrease and growth hormone increase. Conclusions: The combined administration of the transdermal selegiline patch and up to 40 mg cocaine was well tolerated. Selegiline may reduce physiological and subjective effects of cocaine. A randomized trial is needed to evaluate the efficacy of selegiline for cocaine abuse.

AB - Rationale: Because the dopamine system appears to be involved in both acute and chronic effects of cocaine, medication development efforts for cocaine addiction have focused largely on agents that interact with the dopamine system. Selegiline, a selective monoamine oxidase B inhibitor, indirectly modulates dopamine levels, and research suggests selegiline may modify subjective effects of cocaine. Objectives: To evaluate further the safety and potential of transdermal selegiline as a treatment for cocaine dependence, interactions between transdermal selegiline and intravenous cocaine were studied in cocaine-dependent volunteers. Methods: Pharmacokinetics and subjective, physiological, and endocrinological effects of intravenous cocaine (0,20 and 40 mg) were evaluated both before and during transdermal selegiline treatment (20 mg/day, 10 days) in 12 cocaine-dependent subjects. A transdermal selegiline formulation was used to avoid the risks associated with oral administration of MAO inhibitors. Results: Selegiline attenuated some physiological (systolic blood pressure and heart rate) and subjective (good effects, liking, stimulated, high, desire for cocaine) effects of cocaine. Selegiline did not affect cocaine's pharmacokinetics or cocaine-induced prolactin decrease and growth hormone increase. Conclusions: The combined administration of the transdermal selegiline patch and up to 40 mg cocaine was well tolerated. Selegiline may reduce physiological and subjective effects of cocaine. A randomized trial is needed to evaluate the efficacy of selegiline for cocaine abuse.

KW - Cocaine

KW - Eldepryl

KW - Endocrine

KW - Human

KW - Laboratory

KW - Selegiline

KW - Subjective

UR - http://www.scopus.com/inward/record.url?scp=1542314429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542314429&partnerID=8YFLogxK

U2 - 10.1007/s00213-003-1616-6

DO - 10.1007/s00213-003-1616-6

M3 - Article

C2 - 14605792

AN - SCOPUS:1542314429

VL - 172

SP - 31

EP - 40

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 1

ER -